Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

News archive

Recent news


The HARMONY Alliance is a public-private partnership of more than 80 organizations (53 Partners and 35 Associated Members) funded by the Innovative Medicines Initiative for a period of 5 years (2017-2021). Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY Alliance.

Continue reading


Myeloma is the disease with the highest number of approved drugs over the last 15 years. Actually, the prognosis of the disease has been tripled. As myeloma is a very heterogeneous disease, not all treatments are suitable for each patient. The challenge now is to choose the right treatment for each individual patient in order to improve patient health outcomes, increase the value of new medicines to healthcare systems and reduce healthcare costs.

With the aim of providing an overview of personalised medicines in myeloma, Myeloma Patients Europe (MPE) will hold a webinar on Tuesday 25 June from 18:00 to 19:00 CET. Continue reading

More than 12.600 people attended the European Hematology Association (EHA) Annual Meeting, the largest EHA Congress ever recorded with a growth of more than a thousand participants from last year. EHA 2019 was held from 13 to 16 June in Amsterdam, The Netherlands where 360 presentations and more than 1300 posters were presented to update the latest development in haematology. Continue reading

The 24th Congress of the European Hematology Association (EHA) started this Thursday in Amsterdam with the biggest attendance in its history. More than 12.000 attendees get together to discuss the latest developments in haematology.

Continue reading


In addition to providing education, information and support to its 46 member-groups across 30 European countries, Myeloma Patients Europe (MPE) advocates for the best possible research and equal access to the most innovative treatment and care. With this aim, MPE has developed a series of Community Advisory Boards (CABs) focused on myeloma.

Continue reading


The pharmaceutical company Takeda announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory AL amyloidosis did not meet the first of two primary endpoints.

Treatment with ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care regimens. As a result of this analysis, Takeda has decided to discontinue the trial. Continue reading

More than 40,000 people attended the American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2019) which was held in Chicago from 31 May until 4 June. This meeting brings together oncology and haematology professionals from across the globe to discuss the latest scientific and treatment developments in the field.

A number of myeloma topics were presented in this important scientific meeting. The most important updates are outlined below. Continue reading


ASCO 2019, Chicago – New data of a first-in-human (FIH) phase I dose escalation study evaluating AMG 420, a B-cell maturation antigen (BCMA)-targeting BiTE molecule, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Data presented included updated investigational AMG 420 safety and efficacy results in patients with relapsed and/or refractory multiple myeloma (RRMM). BiTE technology is a targeted immuno-oncology platform that is designed to engage patients’ own T cells to a tumor-specific antigen, activating the cytotoxic potential of T cells. Continue reading